Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.
about
Advances in Immunotherapy for Melanoma: A Comprehensive Review.A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.Focus on cutaneous and uveal melanoma specificities.In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME).
P2860
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Safety and immunogenicity of t ...... phase I dose escalation study.
@en
Safety and immunogenicity of t ...... phase I dose escalation study.
@nl
type
label
Safety and immunogenicity of t ...... phase I dose escalation study.
@en
Safety and immunogenicity of t ...... phase I dose escalation study.
@nl
prefLabel
Safety and immunogenicity of t ...... phase I dose escalation study.
@en
Safety and immunogenicity of t ...... phase I dose escalation study.
@nl
P2093
P2860
P50
P1433
P1476
Safety and immunogenicity of t ...... phase I dose escalation study.
@en
P2093
A Hauschild
D Schadendorf
F F Lehmann
P2860
P304
P356
10.1136/ESMOOPEN-2016-000068
P577
2016-08-08T00:00:00Z